Mizagliflozin

From Wikipedia, the free encyclopedia

Legal status
  • Investigational
CAS Number
PubChem CID
ChemSpider
Mizagliflozin
Legal status
Legal status
  • Investigational
Identifiers
  • 2,2-dimethyl-3-([3-{4-[(3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(propan-2-yl)-1H-pyrazol-4-yl)methyl]-3-methylphenoxy}propyl]amino)propanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC28H44N4O8
Molar mass564.680 g·mol−1
3D model (JSmol)
  • Cc1cc(OCCCNCC(C)(C)C(N)=O)ccc1Cc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)n[nH]c1C(C)C
  • InChI=1S/C28H44N4O8/c1-15(2)21-19(25(32-31-21)40-26-24(36)23(35)22(34)20(13-33)39-26)12-17-7-8-18(11-16(17)3)38-10-6-9-30-14-28(4,5)27(29)37/h7-8,11,15,20,22-24,26,30,33-36H,6,9-10,12-14H2,1-5H3,(H2,29,37)(H,31,32)/t20-,22-,23+,24-,26+/m1/s1
  • Key:LREHMKLEOJAVMQ-TXKDOCKMSA-N

Mizagliflozin is an SGLT1 inhibitor developed as a potential treatment for chronic constipation.[1][2] It progressed as far as Phase II trials in humans but was not approved for medical use, however it has since been investigated for other applications.[3][4]

Related Articles

Wikiwand AI